In the soc crossover patients, the tumor is recurrent and might be quite different from the original tumor. Crossover probably helps soc arm patients by perhaps slowing down progression as the recurrent tumor probably has some similar targets to the original. It probably does not help nearly as much for those in the treatment arm since the treatment arm receives the vaccine early and gets DCVax-L that is personalized to the nGBM tumor. As Dr. Ashkan said, there is a benefit to all.